New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events
October 02 2022 - 1:00PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a
new analysis of results from the SOLOIST-WHF Phase 3 outcomes trial
of sotagliflozin, an investigational dual SGLT1 and SGLT2
inhibitor, was presented at the Heart Failure Society of America
(HSFA) Annual Scientific Meeting 2022.
The new analysis was presented by Bertram Pitt,
M.D., FACC, professor of medicine emeritus at the University of
Michigan, School of Medicine, and co-chair for the SOLOIST-WHF
trial as well as a member of the Executive Committee for the Phase
3 SCORED trial of sotagliflozin. The poster, entitled
“Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, Reduces First and
Subsequent Heart Failure-related Events in Patients Admitted for
Worsening Heart Failure”, was presented on Sunday, October 2nd
during the general poster viewing session IV
(https://hfsa.org/hfsa-annual-scientific-meeting-2022).
“Patients treated with sotagliflozin in the
SOLOIST-WHF trial experienced fewer single as well as multiple
heart failure events than those receiving placebo,” said Dr. Pitt.
“Thus, we conclude that sotagliflozin altered the trajectory of
patients hospitalized for worsening heart failure by reducing early
and recurrent heart failure events.”
“We are pleased that data from the SOLOIST-WHF
trial continues to yield robust findings that further help
characterize and differentiate the potential benefits of
sotagliflozin in heart failure,” said Dr. Craig Granowitz,
Lexicon’s senior vice president and chief medical officer.
About the SCORED and SOLOIST-WHF
Studies
SCORED was a multi-center, randomized,
double-blinded, placebo-controlled Phase 3 study evaluating the
cardiovascular efficacy of sotagliflozin versus placebo when added
to standard of care in 10,584 patients with type 2 diabetes,
chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73
m2 of body-surface area, and risks for cardiovascular disease. The
primary endpoint was the total number of events comprised of deaths
from cardiovascular causes, hospitalizations for heart failure, and
urgent visits for heart failure in patients treated with
sotagliflozin compared with placebo. Key secondary endpoints
included total number of events of deaths from cardiovascular
causes, non-fatal myocardial infarction, and non-fatal stroke.
SOLOIST-WHF was a multi-center, randomized,
double-blinded, placebo-controlled Phase 3 study evaluating the
cardiovascular efficacy of sotagliflozin versus placebo when added
to standard of care in 1,222 patients with type 2 diabetes who had
recently been hospitalized for worsening heart failure. The primary
endpoint was the total number of events comprised of deaths from
cardiovascular causes, hospitalizations for heart failure, and
urgent visits for heart failure in patients treated with
sotagliflozin compared with placebo.
Both SCORED and SOLOIST-WHF achieved their
respective primary endpoints, with overall tolerability similar to
placebo across both trials. Results from both studies were
presented at the Late-Breaking Science Session of the American
Heart Association (AHA) Scientific Sessions 2020 and simultaneously
published in The New England Journal of Medicine (NEJM) in two
separate articles titled: “Sotagliflozin in Patients with Diabetes
and Chronic Kidney Disease” and “Sotagliflozin in Patients with
Diabetes and Recent Worsening Heart Failure” which may be accessed
at www.nejm.org.
About Sotagliflozin
Discovered using Lexicon’s unique approach to
gene science, sotagliflozin is an investigational oral dual
inhibitor of two proteins responsible for glucose regulation known
as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2).
SGLT1 is responsible for glucose absorption in the gastrointestinal
tract, and SGLT2 is responsible for glucose reabsorption by the
kidney. Sotagliflozin has been studied in multiple patient
populations encompassing heart failure, type 1 and type 2 diabetes,
and chronic kidney disease in fourteen Phase 3 clinical studies
involving approximately 20,000 patients.
About Lexicon
Pharmaceuticals
Lexicon is a biopharmaceutical company with a
mission of pioneering medicines that transform patients’ lives.
Through its Genome5000™ program, Lexicon scientists studied the
role and function of nearly 5,000 genes and identified more than
100 protein targets with significant therapeutic potential in a
range of diseases. Through the precise targeting of these proteins,
Lexicon is pioneering the discovery and development of innovative
medicines to safely and effectively treat disease. Lexicon advanced
one of these medicines to market and has a pipeline of promising
drug candidates in discovery and clinical and preclinical
development in heart failure, neuropathic pain, diabetes and
metabolism and other indications. For additional information,
please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to the research and
clinical development of, regulatory filings for, and potential
therapeutic and commercial potential of sotagliflozin. In addition,
this press release also contains forward looking statements
relating to Lexicon’s financial position and long-term outlook on
its business, growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including Lexicon’s ability to meet its capital requirements,
successfully conduct preclinical and clinical development and
obtain necessary regulatory approvals of sotagliflozin, LX9211 and
its other potential drug candidates on its anticipated timelines,
successfully commercialize any products for which it obtains
regulatory approval, achieve its operational objectives, obtain
patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates. Any of these risks, uncertainties and
other factors may cause Lexicon’s actual results to be materially
different from any future results expressed or implied by such
forward-looking statements. Information identifying such important
factors is contained under “Risk Factors” in Lexicon’s annual
report on Form 10-K for the year ended December 31, 2021, as filed
with the Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
For Inquiries:
Mike KellyLexicon Pharmaceuticals,
Inc.mkelly@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024